Disease/Infection News

RSS

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).

27 Apr 2015

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.

25 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Systematic review shows hepatitis B and C testing lacking in many European countries

The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver Congress 2015.

25 Apr 2015

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

Multicentre study provides hope for malaria therapy with just one dose

Approximately 584,000 people worldwide die of malaria each year. The epidemic strongly associated with poverty claims most of its victims in Africa, where it particularly affects the weakest, children and pregnant women. Current therapies have to be taken over several days to be effective against malaria.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study.

25 Apr 2015

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

25 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Dry eye strikes most often in spring

New ophthalmology research from the University of Miami shows that dry eye - the little understood culprit behind red, watery, gritty feeling eyes - strikes most often in spring, just as airborne allergens are surging.

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Common tapeworm drug effectively treats MRSA superbugs in lab

A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.

24 Apr 2015

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

A group of leading scientists has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is spent on developing new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

24 Apr 2015

Copley Scientific to showcase new accessories at RDD Europe 2015

Cascade impaction is used for all inhaled product testing but is a manually intensive process. Copley Scientific’s sample preparation tools help to alleviate bottlenecks, ensure that testing is consistent, reproducible and controlled, and also reduce the risk of repetitive strain injury (RSI)...

24 Apr 2015

Mobidiag to present two new diagnostic platforms for infectious diseases at ECCMID 2015

Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.

24 Apr 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

24 Apr 2015

Recommended alcoholic hepatitis treatments fail to increase patients' survival

The main drugs used to treat alcoholic hepatitis are not effective at increasing patients' survival, a major study has found. In a trial of over 1,000 patients, prednisolone and pentoxifylline, treatments recommended in international guidelines, did not achieve a statistically significant reduction in mortality after 28 days, 90 days or a year.

24 Apr 2015

Disease/Infection News

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Systematic review shows hepatitis B and C testing lacking in many European countries

Occurrence of advanced liver fibrosis similar for patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Multicentre study provides hope for malaria therapy with just one dose

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Study shows NASH linked to 50% higher death rates compared with NAFLD

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Dry eye strikes most often in spring

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Common tapeworm drug effectively treats MRSA superbugs in lab

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Copley Scientific to showcase new accessories at RDD Europe 2015

Mobidiag to present two new diagnostic platforms for infectious diseases at ECCMID 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Recommended alcoholic hepatitis treatments fail to increase patients' survival

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News